

FOR IMMEDIATE RELEASE:

Chaperone Therapeutics, Inc. receives award from The Michael J. Fox Foundation to develop therapies for Parkinson's disease

CHAPEL HILL, NC, November 30, 2009: Chaperone Therapeutics, Inc. announced today that it has been awarded grant funds from The Michael J. Fox Foundation's *Novel Approaches to Drug Discovery for Parkinson's Disease* program to fund the development of small molecular compounds for the treatment of Parkinson's disease.

This award will fund the optimization of Chaperone's proprietary drug leads. "We are delighted to have the support of The Michael J. Fox Foundation. This funding is critical to Chaperone's mission to develop treatments for this devastating disease," said Chaperone's President and CEO William Janzen.

Parkinson's disease is characterized by protein aggregation and neurodegeneration and is thought to affect over one million people in the United States and nearly five million people world-wide. Chaperone's proprietary small molecules enhance the correct folding of proteins, protein solubility and cellular quality control mechanisms through elevating protein chaperone production in living cells.

About Chaperone Therapeutics:

Chaperone is an early stage pharmaceutical company located in Chapel Hill, North Carolina that is developing therapies for the treatment of neurodegenerative diseases. Many neurodegenerative diseases that currently have only palliative treatments have underlying defects in protein folding and aggregation. These include neurodegenerative diseases in which the enhancement of protein folding capability shows therapeutic potential and include Parkinson's disease, Alzheimer's disease, prion diseases, ALS/ Lou Gehrig's Disease and Huntington's Disease.

For further information please contact:

Maria Sippola-Thiele, Ph.D., M.B.A.
Chief Technology and Business Officer
Chaperone Therapeutics, Inc.
sippolathiele@chaperonetherapeutics.com